Top 1% Biotech, A Merck Rival, Plummets On A Surprise Failure - Investor's Business Daily
07.06.2025 12:16
Patients treate… [+2487 chars]
Summit Therapeutics (SMMT) stock plunged Friday after its highly-watched cancer drug slowed progression, but failed to significantly improve overall survival in lung cancer patients.